Dr. D’Angelo on Emerging Therapies in DLBCL

Video

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

Christopher R. D’Angelo, MD, assistant professor, Division of Hematology & Oncology, The University of Nebraska Medical Center, discusses emerging therapies in diffuse large B-cell lymphoma (DLBCL).

In the genomic landscape of DLBCL, some pathways have been identified as attractive and hyperactive targets, D’Angelo says. For instance, proteolysis targeting chimeras (PROTACs), an evolving therapy in DLBCL, were presented in a discussion of a phase 1 study (NCT04830137) at the 2022 ASCO Annual Meeting, D’Angelo notes.

PROTACs work by linking a target to a cell’s E3 ubiquitin ligase recruiting ligand, a proteasome degradation system, which causes a more thorough degradation of the target than binding agents do, D’Angelo explains. PROTACs have been used to target and degrade BTK, offering a potential advantage over covalent and noncovalent BTK inhibitors, D’Angelo says.

The phase 1 trial is currently recruiting patients with a variety of B-cell non-Hodgkin lymphomas, including DLBCL, D’Angelo notes. PROTACs have displayed preliminary efficacy in non-germinal center B-cell–like DLBCL, and further findings in that population and others are awaited, D’Angelo concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD